ENLV20260821C1.5
ENLV Aug 21 2026 1.50 Call (ENLV260821C00001500)
option OPRA

enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib clinical trial in patients with severe sepsis; that is in investigator-initiated phase ii clinical trial for the treatment of covid-19 patients in severe and critical conditions; and which is in phase iia clinical trial for the prevention of graft versus host disease in allogeneic hematopoietic stem cell transplants (hsct) patients. the company is also developing allocetra for the prevention of complications associated with bone marrow transplantations and/or hsct, and acute multiple organ failure. it also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor t-cell therapy and therapies targeting t-cell re